Akio Nakashima
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Akio Nakashima has a total of 176 co-authors. Here are the top co-authors by number of shared publications:
Ichiro Ohkido
Division of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, 3-25-8, Nishi-Shimbashi, Minato-ku, Tokyo, Japan
20 shared publicationsTakashi Yokoo
Division of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, 3-25-8, Nishi-Shimbashi, Minato-ku, Tokyo, Japan
20 shared publications- Takashi Yokoo
Division of Nephrology and Hypertension, Department of Internal Medicine, Jikei University School of medicine, Tokyo, Japan
11 shared publications Arisa Kobayashi
Division of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, 3-25-8, Nishi-Shimbashi, Minato-ku, Tokyo, Japan
10 shared publicationsKazuhiko Kato
Division of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, 3-25-8, Nishi-Shimbashi, Minato-ku, Tokyo, Japan
10 shared publications- Mitsuyoshi Urashima
Division of Molecular Epidemiology, The Jikei University School of Medicine, 3-25-8, Nishi-Shimbashi, Minato-Ku, Tokyo 105-8461, Japan
8 shared publications
Latest Publications
- Open Access
- 5 August 2026
- Published by Oxford University Press (OUP) in JBMR Plus
- Vol. 10 (10)
Bone turnover markers associated with cognitive dysfunction in patients undergoing hemodialysis: a cross-sectional study
Cognitive impairment is common in patients undergoing hemodialysis; however, evidence linking routinely measured bone turnover markers to cognition remains limited. In this exploratory cross-sectional study, we aimed to evaluate whether bone-specific alkaline phosphatase (BAP), total alkaline phosphatase (ALP), and tartrate-resistant acid phosphatase 5b (TRACP-5b) are related to global cognitive function in older patients undergoing hemodialysis. Adults aged ≥65 yr receiving maintenance hemodialysis were enrolled at seven centers in Tokyo and Chiba, Japan (November 2021-November 2022). Global cognition was assessed using the Montreal Cognitive Assessment (MoCA) and Mini-Mental State Examination (MMSE). Multivariable linear regression with robust SEs and facility fixed effects was used to examine associations with MoCA scores across sequentially adjusted models. Because of a ceiling effect, MMSE was analyzed using logistic regression with MMSE ≤23 as the outcome (unadjusted and age-/sex-adjusted). For statistical analyses, bone turnover markers were natural log-transformed. Among 380 participants (median age 74 yr; 67.6% male), higher BAP was consistently associated with lower MoCA scores (fully adjusted β −1.03; 95% CI, −1.90 to −0.16). Total ALP showed inverse associations in less-adjusted models; however, these associations attenuated after full adjustment (β −.88; 95% CI, −1.89 to 0.14). TRACP-5b was not clearly associated with MoCA scores. Higher BAP and total ALP were associated with higher odds of MMSE-defined cognitive dysfunction, whereas TRACP-5b was not. These findings suggest a potential association between bone formation-related markers and cognitive performance in older patients undergoing hemodialysis. Prospective and mechanistic studies are warranted to clarify causality and clinical utility.
- 5 August 2026
- Published by Oxford University Press (OUP) in JBMR Plus
- Vol. 10 (10)
Open AccessBone turnover markers associated with cognitive dysfunction in patients undergoing hemodialysis: a cross-sectional study
Cognitive impairment is common in patients undergoing hemodialysis; however, evidence linking routinely measured bone turnover markers to cognition remains limited. In this exploratory cross-sectional study, we aimed to evaluate whether bone-specific alkaline phosphatase (BAP), total alkaline phosphatase (ALP), and tartrate-resistant acid phosphatase 5b (TRACP-5b) are related to global cognitive function in older patients undergoing hemodialysis. Adults aged ≥65 yr receiving maintenance hemodialysis were enrolled at seven centers in Tokyo and Chiba, Japan (November 2021-November 2022). Global cognition was assessed using the Montreal Cognitive Assessment (MoCA) and Mini-Mental State Examination (MMSE). Multivariable linear regression with robust SEs and facility fixed effects was used to examine associations with MoCA scores across sequentially adjusted models. Because of a ceiling effect, MMSE was analyzed using logistic regression with MMSE ≤23 as the outcome (unadjusted and age-/sex-adjusted). For statistical analyses, bone turnover markers were natural log-transformed. Among 380 participants (median age 74 yr; 67.6% male), higher BAP was consistently associated with lower MoCA scores (fully adjusted β −1.03; 95% CI, −1.90 to −0.16). Total ALP showed inverse associations in less-adjusted models; however, these associations attenuated after full adjustment (β −.88; 95% CI, −1.89 to 0.14). TRACP-5b was not clearly associated with MoCA scores. Higher BAP and total ALP were associated with higher odds of MMSE-defined cognitive dysfunction, whereas TRACP-5b was not. These findings suggest a potential association between bone formation-related markers and cognitive performance in older patients undergoing hemodialysis. Prospective and mechanistic studies are warranted to clarify causality and clinical utility.
- Open Access
- 22 June 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Association between soluble Klotho levels and calcification propensity T50 in patients with hemodialysis: a cross-sectional study
Soluble Klotho is an anti-aging hormone implicated in vascular calcification. The calcification propensity score (T50) is a method used to evaluate the calcification propensity. However, no study has evaluated the association between soluble Klotho and T50. Therefore, this study aimed to investigate the association between soluble Klotho and T50 in patients undergoing hemodialysis. This cross-sectional study recruited patients undergoing hemodialysis. We measured T50 using the turbidimetric method and soluble Klotho using an enzyme-linked immunosorbent assay. Multiple regression analysis was used to examine the association between soluble Klotho and T50. In total, 199 patients were included in this study. Patients' mean age was 65.2 ± 10.2 years, and the median soluble Klotho concentration was 408 (321-525) pg/mL. The serum T50 value was 78 (63-104) minutes. The correlation coefficient between T50 and soluble Klotho was 0.39 (p < 0.001). Multivariate analysis revealed that the T50 value was significantly longer when comparing the group with the lowest and highest Klotho concentrations (β-coefficient = 21.3 [95% confidence interval: 4.5-38.2, p < 0.013]). The analysis of hemodialysis patients revealed for the first time that Klotho is associated with the T50 time. Soluble Klotho may be involved in vascular calcification.
- 22 June 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessAssociation between soluble Klotho levels and calcification propensity T50 in patients with hemodialysis: a cross-sectional study
Soluble Klotho is an anti-aging hormone implicated in vascular calcification. The calcification propensity score (T50) is a method used to evaluate the calcification propensity. However, no study has evaluated the association between soluble Klotho and T50. Therefore, this study aimed to investigate the association between soluble Klotho and T50 in patients undergoing hemodialysis. This cross-sectional study recruited patients undergoing hemodialysis. We measured T50 using the turbidimetric method and soluble Klotho using an enzyme-linked immunosorbent assay. Multiple regression analysis was used to examine the association between soluble Klotho and T50. In total, 199 patients were included in this study. Patients' mean age was 65.2 ± 10.2 years, and the median soluble Klotho concentration was 408 (321-525) pg/mL. The serum T50 value was 78 (63-104) minutes. The correlation coefficient between T50 and soluble Klotho was 0.39 (p < 0.001). Multivariate analysis revealed that the T50 value was significantly longer when comparing the group with the lowest and highest Klotho concentrations (β-coefficient = 21.3 [95% confidence interval: 4.5-38.2, p < 0.013]). The analysis of hemodialysis patients revealed for the first time that Klotho is associated with the T50 time. Soluble Klotho may be involved in vascular calcification.
- 26 May 2026
- Published by Springer Nature in Clinical and Experimental Nephrology
- Vol. 30 (8) , 1237-1244
High-density lipoprotein cholesterol and cognitive function in patients undergoing hemodialysis
Cognitive impairment is highly prevalent among older adults receiving maintenance hemodialysis; however, its pathophysiology is multifactorial and poorly understood. Evidence linking the lipid-profile components to cognitive function in patients undergoing hemodialysis remains limited. To address this evidence gap, we evaluated the associations between serum lipid-profile components and global cognitive function. We conducted an exploratory cross-sectional study of patients aged ≥ 65 years receiving maintenance hemodialysis at seven dialysis centers in Japan. Serum high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and triglyceride (TG) levels were measured immediately before the first hemodialysis session of the week. Global cognitive function was assessed using the Montreal Cognitive Assessment (MoCA) and the Mini-Mental State Examination (MMSE). Multivariate linear regression analyses were performed, adjusting for clinical comorbidities and markers of nutritional status, inflammation, and dialysis adequacy. Among 265 participants (median age, 74 years; 67.6% male), higher serum HDL-C levels were independently associated with higher MoCA scores (fully adjusted model: β = 0.06; 95% confidence interval, 0.03-0.10; P < 0.001) and MMSE scores (β = 0.03; 95% confidence interval, 0.01-0.06; P = 0.031). In contrast, the serum LDL-C and TG levels showed no significant associations with either cognitive assessment. Higher serum HDL-C levels were associated with better global cognitive function in older patients undergoing hemodialysis, whereas the LDL-C and TG levels were not significantly related to cognitive scores.
- 26 May 2026
- Published by Springer Nature in Clinical and Experimental Nephrology
- Vol. 30 (8) , 1237-1244
High-density lipoprotein cholesterol and cognitive function in patients undergoing hemodialysis
Cognitive impairment is highly prevalent among older adults receiving maintenance hemodialysis; however, its pathophysiology is multifactorial and poorly understood. Evidence linking the lipid-profile components to cognitive function in patients undergoing hemodialysis remains limited. To address this evidence gap, we evaluated the associations between serum lipid-profile components and global cognitive function. We conducted an exploratory cross-sectional study of patients aged ≥ 65 years receiving maintenance hemodialysis at seven dialysis centers in Japan. Serum high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and triglyceride (TG) levels were measured immediately before the first hemodialysis session of the week. Global cognitive function was assessed using the Montreal Cognitive Assessment (MoCA) and the Mini-Mental State Examination (MMSE). Multivariate linear regression analyses were performed, adjusting for clinical comorbidities and markers of nutritional status, inflammation, and dialysis adequacy. Among 265 participants (median age, 74 years; 67.6% male), higher serum HDL-C levels were independently associated with higher MoCA scores (fully adjusted model: β = 0.06; 95% confidence interval, 0.03-0.10; P < 0.001) and MMSE scores (β = 0.03; 95% confidence interval, 0.01-0.06; P = 0.031). In contrast, the serum LDL-C and TG levels showed no significant associations with either cognitive assessment. Higher serum HDL-C levels were associated with better global cognitive function in older patients undergoing hemodialysis, whereas the LDL-C and TG levels were not significantly related to cognitive scores.
- 19 May 2026
- Published by Oxford University Press (OUP) in Journal Of Nephrology
Programmed cell death 1 pathway and cognitive function in patients undergoing hemodialysis
Background: Cognitive impairment is common among patients undergoing hemodialysis and worsens their quality of life and survival. The programmed cell death 1 (PD-1) pathway—comprising the receptor PD-1 and its ligand programmed cell death ligand 1 (PD-L1)—was initially recognized as a mechanism of tumor immune evasion that was also involved in chronic inflammation and immune aging. However, its role in cognitive impairment remains poorly understood. Methods: In this cross-sectional study, patients aged ≥65 years undergoing hemodialysis were recruited from 7 centers. Global cognitive function was assessed by the Montreal Cognitive Assessment (MoCA) and Mini-Mental State Examination (MMSE). Serum soluble PD-1 (sPD-1) and soluble PD-L1 (sPD-L1) were measured by enzyme-linked immunosorbent assay. Multivariable logistic regression was used to adjust for age, sex, dialysis vintage, C-reactive protein, and other confounders. Results: Median age of the 384 patients was 74 years (interquartile range, 70–80), 67.5% were male, 61.2% scored below the MoCA score cutoff of 26, and 10.2% scored below the MMSE score cutoff of 24. Higher sPD-1 levels were associated with cognitive impairment as defined by both assessment tools; moreover, higher sPD-L1 levels were associated with MoCA-defined impairment (odds ratio, 2.53; 95% confidence interval, 1.26–5.06, P = .009). The association between sPD-1 and MMSE-defined impairment was stronger in patients without cancer history. Conclusion: These findings highlight the potential role of the PD-1 pathway in risk stratification and future interventions in cognitive impairment in patients undergoing hemodialysis.
- 19 May 2026
- Published by Oxford University Press (OUP) in Journal Of Nephrology
Programmed cell death 1 pathway and cognitive function in patients undergoing hemodialysis
Background: Cognitive impairment is common among patients undergoing hemodialysis and worsens their quality of life and survival. The programmed cell death 1 (PD-1) pathway—comprising the receptor PD-1 and its ligand programmed cell death ligand 1 (PD-L1)—was initially recognized as a mechanism of tumor immune evasion that was also involved in chronic inflammation and immune aging. However, its role in cognitive impairment remains poorly understood. Methods: In this cross-sectional study, patients aged ≥65 years undergoing hemodialysis were recruited from 7 centers. Global cognitive function was assessed by the Montreal Cognitive Assessment (MoCA) and Mini-Mental State Examination (MMSE). Serum soluble PD-1 (sPD-1) and soluble PD-L1 (sPD-L1) were measured by enzyme-linked immunosorbent assay. Multivariable logistic regression was used to adjust for age, sex, dialysis vintage, C-reactive protein, and other confounders. Results: Median age of the 384 patients was 74 years (interquartile range, 70–80), 67.5% were male, 61.2% scored below the MoCA score cutoff of 26, and 10.2% scored below the MMSE score cutoff of 24. Higher sPD-1 levels were associated with cognitive impairment as defined by both assessment tools; moreover, higher sPD-L1 levels were associated with MoCA-defined impairment (odds ratio, 2.53; 95% confidence interval, 1.26–5.06, P = .009). The association between sPD-1 and MMSE-defined impairment was stronger in patients without cancer history. Conclusion: These findings highlight the potential role of the PD-1 pathway in risk stratification and future interventions in cognitive impairment in patients undergoing hemodialysis.
- 3 April 2026
- Published by Springer Nature in Clinical and Experimental Nephrology
- Vol. 30 (6) , 914-922
Correlation and dissociation factors between ionized, total, and corrected calcium in patients undergoing hemodialysis
Background Ionized calcium (iCa) has physiological activity in the body; however, the direct measurement of iCa is technically limited. Although total serum calcium (tCa) and corrected serum calcium (cCa) using the Payne correction formula have been used to assess calcium levels, their limitations have been noted. We aimed to clarify the degree of correlation and dissociation among iCa, tCa, and cCa levels in patients undergoing hemodialysis. Methods This cross-sectional study assessed the correlation between iCa, tCa, and cCa levels in patients undergoing hemodialysis. Factors involved in the correlation between iCa and tCa levels were evaluated using multiple regression analysis. Based on these results, we proposed a novel iCa prediction equation. Results Two hundred and thirteen patients were enrolled. The median patient age was 65 (standard deviation, 10.2) years, and 68.2% of patients were male. The correlation coefficients were 0.867 for iCa and tCa and 0.854 for iCa and cCa. Correlations were also observed when albumin concentrations and pH were divided, both of which are known correlation factors. In multiple regression analysis of the relationship between tCa and iCa, sex, pH, albumin, phosphate, and magnesium levels were significant factors. We established a new corrected calcium equation using age and albumin level: (mg/dL) = 0.828 × total calcium − 0.314 × albumin (g/dL) + 0.007 × age + 2.922. Conclusions iCa, tCa, and cCa had a correlation in patients undergoing hemodialysis, with a stronger correlation with tCa in iCa assessments.
- 3 April 2026
- Published by Springer Nature in Clinical and Experimental Nephrology
- Vol. 30 (6) , 914-922
Correlation and dissociation factors between ionized, total, and corrected calcium in patients undergoing hemodialysis
Background Ionized calcium (iCa) has physiological activity in the body; however, the direct measurement of iCa is technically limited. Although total serum calcium (tCa) and corrected serum calcium (cCa) using the Payne correction formula have been used to assess calcium levels, their limitations have been noted. We aimed to clarify the degree of correlation and dissociation among iCa, tCa, and cCa levels in patients undergoing hemodialysis. Methods This cross-sectional study assessed the correlation between iCa, tCa, and cCa levels in patients undergoing hemodialysis. Factors involved in the correlation between iCa and tCa levels were evaluated using multiple regression analysis. Based on these results, we proposed a novel iCa prediction equation. Results Two hundred and thirteen patients were enrolled. The median patient age was 65 (standard deviation, 10.2) years, and 68.2% of patients were male. The correlation coefficients were 0.867 for iCa and tCa and 0.854 for iCa and cCa. Correlations were also observed when albumin concentrations and pH were divided, both of which are known correlation factors. In multiple regression analysis of the relationship between tCa and iCa, sex, pH, albumin, phosphate, and magnesium levels were significant factors. We established a new corrected calcium equation using age and albumin level: (mg/dL) = 0.828 × total calcium − 0.314 × albumin (g/dL) + 0.007 × age + 2.922. Conclusions iCa, tCa, and cCa had a correlation in patients undergoing hemodialysis, with a stronger correlation with tCa in iCa assessments.
- Open Access
- 20 February 2026
- Published by Wolters Kluwer Health in Kidney360
- Vol. 7 (6) , 1307-1315
Neurofilament Light Chain and Cognitive Dysfunction in Patients Undergoing Hemodialysis
Key Points: Blood biomarkers related to amyloid β and neurofilament light chain are used to predict cognitive decline in the general population. Evidence for their usefulness is lacking in patients receiving hemodialysis despite their high risk of cognitive impairment. Neurofilament light chain levels were negatively associated with cognitive function, whereas the amyloid β ratio was not. Background: Cognitive dysfunction is frequently observed in patients undergoing hemodialysis in clinical settings; however, its pathophysiology remains uncertain. In recent years, noninvasive blood biomarkers have garnered increasing attention in predicting Alzheimer's disease development. Within the general population, neurofilament light chain (NfL) levels have been used to prognosticate changes in cognitive function alongside the amyloid β (A β ) 1–42/1–40 ratio. Nevertheless, this has not been studied in patients with CKD, particularly those undergoing hemodialysis. Methods: This exploratory cross-sectional study investigated the association of the serum A β 1–42/1–40 ratio and NfL levels with cognitive function assessed using the Montreal Cognitive Assessment (MoCA) and Mini-Mental State Examination (MMSE), in patients undergoing hemodialysis. Results: We included 384 patients with a median age of 74 (interquartile range [IQR], 70–80) years. The median (IQR) MoCA and MMSE scores were 25 (22–26) and 28 (26–29), respectively. The median (IQR) A β 1–42/1–40 ratio and NfL level were 0.04 (0.03–0.06) and 196.2 pg/ml (146.5–262.2), respectively. The multivariate linear regression analysis indicated a weak negative association between the log-transformed NfL levels and cognitive function, after adjusting for confounding factors including age ( β coefficient [95% confidence interval], −0.98 [−1.81 to −0.15]; P = 0.021 for MoCA and −0.66 [−1.32 to −0.01]; P = 0.046 for MMSE). However, the A β 1–42/1–40 ratio was not associated with cognitive function. Conclusions: Our exploratory analysis identified a weak negative association between serum NfL levels and cognitive function in patients undergoing hemodialysis.
- 20 February 2026
- Published by Wolters Kluwer Health in Kidney360
- Vol. 7 (6) , 1307-1315
Open AccessNeurofilament Light Chain and Cognitive Dysfunction in Patients Undergoing Hemodialysis
Key Points: Blood biomarkers related to amyloid β and neurofilament light chain are used to predict cognitive decline in the general population. Evidence for their usefulness is lacking in patients receiving hemodialysis despite their high risk of cognitive impairment. Neurofilament light chain levels were negatively associated with cognitive function, whereas the amyloid β ratio was not. Background: Cognitive dysfunction is frequently observed in patients undergoing hemodialysis in clinical settings; however, its pathophysiology remains uncertain. In recent years, noninvasive blood biomarkers have garnered increasing attention in predicting Alzheimer's disease development. Within the general population, neurofilament light chain (NfL) levels have been used to prognosticate changes in cognitive function alongside the amyloid β (A β ) 1–42/1–40 ratio. Nevertheless, this has not been studied in patients with CKD, particularly those undergoing hemodialysis. Methods: This exploratory cross-sectional study investigated the association of the serum A β 1–42/1–40 ratio and NfL levels with cognitive function assessed using the Montreal Cognitive Assessment (MoCA) and Mini-Mental State Examination (MMSE), in patients undergoing hemodialysis. Results: We included 384 patients with a median age of 74 (interquartile range [IQR], 70–80) years. The median (IQR) MoCA and MMSE scores were 25 (22–26) and 28 (26–29), respectively. The median (IQR) A β 1–42/1–40 ratio and NfL level were 0.04 (0.03–0.06) and 196.2 pg/ml (146.5–262.2), respectively. The multivariate linear regression analysis indicated a weak negative association between the log-transformed NfL levels and cognitive function, after adjusting for confounding factors including age ( β coefficient [95% confidence interval], −0.98 [−1.81 to −0.15]; P = 0.021 for MoCA and −0.66 [−1.32 to −0.01]; P = 0.046 for MMSE). However, the A β 1–42/1–40 ratio was not associated with cognitive function. Conclusions: Our exploratory analysis identified a weak negative association between serum NfL levels and cognitive function in patients undergoing hemodialysis.
- Open Access
- 31 July 2025
- Published by Elsevier in Kidney International Reports
- Vol. 10 (10) , 3516-3526
Klotho’s Impact on Cardiovascular Disease, Fractures, and Mortality in Hemodialysis
- 31 July 2025
- Published by Elsevier in Kidney International Reports
- Vol. 10 (10) , 3516-3526
Open AccessKlotho’s Impact on Cardiovascular Disease, Fractures, and Mortality in Hemodialysis
- Open Access
- 15 July 2025
- Published by Springer Nature in Renal Replacement Therapy
- Vol. 11 (1) , 1-8
Impact of blood urea nitrogen to creatinine ratio on infectious events, cardiovascular events, and all-cause mortality in patients with hemodialysis: a retrospective cohort study
Background: In patients undergoing hemodialysis, serum blood urea nitrogen (BUN) and creatinine (Cr) levels are affected by factors such as diet and muscle mass. Few studies have examined the optimal range of serum BUN/Cr ratios in these patients. Therefore, this study examined the association between the BUN/Cr ratio and all-cause mortality. Methods: This retrospective cohort study evaluated pre-dialysis BUN/Cr ratios. Cox regression analysis was performed with all-cause mortality as the outcome and the BUN/Cr ratio as an explanatory factor. Results: This study included 1321 patients undergoing hemodialysis (mean age: 63.5 ± 11.7 years; dialysis duration: 110 [17–203] months; 70.0% male). The mean serum BUN was 65.1 ± 14.1 mg/dL, Cr was 11.5 ± 3.1 mg/dL, and BUN/Cr ratio was 5.97 ± 2.26. During the study, 253 deaths occurred. Using the group with the second-lowest serum BUN/Cr ratio (4.7–5.6) as a reference, the highest BUN/Cr ratio (> 6.8) was associated with a significantly higher mortality rate (hazard ratio [HR], 1.98; 95% confidence interval [95% CI], 1.30–3.03), and the second-highest group (5.6–6.8) had an increased risk of major cardiovascular disease events (HR, 1.67; 95% CI, 1.22–2.28) and infectious events (HR, 1.59; 95% CI, 1.04–2.45). Conclusion: Elevated BUN/Cr ratios were associated with increased risks of infectious events, cardiovascular events, and all-cause mortality in patients undergoing hemodialysis.
- 15 July 2025
- Published by Springer Nature in Renal Replacement Therapy
- Vol. 11 (1) , 1-8
Open AccessImpact of blood urea nitrogen to creatinine ratio on infectious events, cardiovascular events, and all-cause mortality in patients with hemodialysis: a retrospective cohort study
Background: In patients undergoing hemodialysis, serum blood urea nitrogen (BUN) and creatinine (Cr) levels are affected by factors such as diet and muscle mass. Few studies have examined the optimal range of serum BUN/Cr ratios in these patients. Therefore, this study examined the association between the BUN/Cr ratio and all-cause mortality. Methods: This retrospective cohort study evaluated pre-dialysis BUN/Cr ratios. Cox regression analysis was performed with all-cause mortality as the outcome and the BUN/Cr ratio as an explanatory factor. Results: This study included 1321 patients undergoing hemodialysis (mean age: 63.5 ± 11.7 years; dialysis duration: 110 [17–203] months; 70.0% male). The mean serum BUN was 65.1 ± 14.1 mg/dL, Cr was 11.5 ± 3.1 mg/dL, and BUN/Cr ratio was 5.97 ± 2.26. During the study, 253 deaths occurred. Using the group with the second-lowest serum BUN/Cr ratio (4.7–5.6) as a reference, the highest BUN/Cr ratio (> 6.8) was associated with a significantly higher mortality rate (hazard ratio [HR], 1.98; 95% confidence interval [95% CI], 1.30–3.03), and the second-highest group (5.6–6.8) had an increased risk of major cardiovascular disease events (HR, 1.67; 95% CI, 1.22–2.28) and infectious events (HR, 1.59; 95% CI, 1.04–2.45). Conclusion: Elevated BUN/Cr ratios were associated with increased risks of infectious events, cardiovascular events, and all-cause mortality in patients undergoing hemodialysis.
- Open Access
- 15 January 2025
- Published by Oxford University Press (OUP) in JBMR Plus
- Vol. 9 (3) , ziae178
Parathyroid hormone-related protein levels and treatment outcomes in hypercalcemia of malignancy: a retrospective cohort study
The challenge of managing acute hypercalcemia in patients diagnosed with hypercalcemia of malignancy (HCM) merits further attention. Elevated levels of PTHrP may be a risk factor for treatment resistance in acute hypercalcemia; however, few studies have tested this hypothesis. This study aimed to investigate whether high PTHrP levels represent an independent risk factor that impedes the treatment of acute hypercalcemia. This retrospective cohort study recruited 159 patients aged 20-80 years with diagnosed malignancies who had been hospitalized for hypercalcemia with PTHrP levels above the reference value (1.1 pmol/L). The median (25%-75%) patient age was 69 (61-76) years, and the median PTHrP level was 6.3 (3.3-11.1) pmol/L. The corrected calcium levels decreased from 12.8 mg/dL (11.9-14.1 mg/dL) to 10.6 mg/dL (9.8-11.7 mg/dL) following treatments, such as bisphosphonates and saline solution. Multivariate linear regression analysis showed less significant decreases in the corrected calcium levels as natural logarithm-transformed PTHrP levels increased (β coefficient [95% CI]: 0.569 [0.225-0.914]; p = .001 for Model 3). Multivariate logistic regression analysis showed an association between high natural logarithm-transformed PTHrP levels and lack of treatment response, defined as a corrected calcium level of ≤10.4 mg/dL in the last blood test conducted within 2 wk of treatment initiation (odds ratio [95% CI]: 0.504 [0.312-0.814]; p = .005). Therefore, elevated PTHrP levels are a potential risk factor for treatment resistance in hypercalcemia in HCM patients, complicating management regardless of calcium levels.
- 15 January 2025
- Published by Oxford University Press (OUP) in JBMR Plus
- Vol. 9 (3) , ziae178
Open AccessParathyroid hormone-related protein levels and treatment outcomes in hypercalcemia of malignancy: a retrospective cohort study
The challenge of managing acute hypercalcemia in patients diagnosed with hypercalcemia of malignancy (HCM) merits further attention. Elevated levels of PTHrP may be a risk factor for treatment resistance in acute hypercalcemia; however, few studies have tested this hypothesis. This study aimed to investigate whether high PTHrP levels represent an independent risk factor that impedes the treatment of acute hypercalcemia. This retrospective cohort study recruited 159 patients aged 20-80 years with diagnosed malignancies who had been hospitalized for hypercalcemia with PTHrP levels above the reference value (1.1 pmol/L). The median (25%-75%) patient age was 69 (61-76) years, and the median PTHrP level was 6.3 (3.3-11.1) pmol/L. The corrected calcium levels decreased from 12.8 mg/dL (11.9-14.1 mg/dL) to 10.6 mg/dL (9.8-11.7 mg/dL) following treatments, such as bisphosphonates and saline solution. Multivariate linear regression analysis showed less significant decreases in the corrected calcium levels as natural logarithm-transformed PTHrP levels increased (β coefficient [95% CI]: 0.569 [0.225-0.914]; p = .001 for Model 3). Multivariate logistic regression analysis showed an association between high natural logarithm-transformed PTHrP levels and lack of treatment response, defined as a corrected calcium level of ≤10.4 mg/dL in the last blood test conducted within 2 wk of treatment initiation (odds ratio [95% CI]: 0.504 [0.312-0.814]; p = .005). Therefore, elevated PTHrP levels are a potential risk factor for treatment resistance in hypercalcemia in HCM patients, complicating management regardless of calcium levels.
- Open Access
- 10 January 2025
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 18 (2) , sfae391
Parathyroid gland volume and treatment resistance in patients with secondary hyperparathyroidism: a 4-year retrospective cohort study
Background: The role of parathyroid gland (PTG) ultrasonography in the management of secondary hyperparathyroidism after the introduction of calcimimetics remains unclear. Recent investigations have prompted renewed interest in the use of PTG ultrasonography for assessing treatment resistance to calcimimetics and determining the optimal timing for surgical intervention. This study aimed to explore the hypothesis that the PTG volume correlates with the calcimimetic dose. Methods: We retrospectively observed outpatients undergoing haemodialysis at baseline and a 4-year follow-up. PTG volume was measured using ultrasonography between January and December 2017 and January and December 2021. We examined the association between baseline PTG volume and calcimimetic doses after 4 years. Results: Of the 121 patients {median age 64 years [interquartile range (IQR) 54–72]}, 71 had PTG nodules on ultrasonography and the median total PTG volume was 34 mm3 (IQR 0–178). In the short dialysis vintage group, baseline parathyroid hormone levels tended to correlate with baseline calcimimetic doses; however, this trend was not observed in the extended dialysis vintage group. Baseline PTG volume correlated with the cinacalcet-equivalent calcimimetic dose (correlation coefficient 0.46; P < .001) after 4 years. The calcimimetic dose in the group with an estimated PTG volume >500 mm3 was ≈80 mg/day higher than that in the non-PTG nodule group after 4 years. In multivariate linear regression analysis, PTG volume >500 mm3 was associated with a high calcimimetic dose at 4 years in all analysis models. Conclusions: Assessing PTG volume using ultrasonography may help predict high calcimimetic doses.
- 10 January 2025
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 18 (2) , sfae391
Open AccessParathyroid gland volume and treatment resistance in patients with secondary hyperparathyroidism: a 4-year retrospective cohort study
Background: The role of parathyroid gland (PTG) ultrasonography in the management of secondary hyperparathyroidism after the introduction of calcimimetics remains unclear. Recent investigations have prompted renewed interest in the use of PTG ultrasonography for assessing treatment resistance to calcimimetics and determining the optimal timing for surgical intervention. This study aimed to explore the hypothesis that the PTG volume correlates with the calcimimetic dose. Methods: We retrospectively observed outpatients undergoing haemodialysis at baseline and a 4-year follow-up. PTG volume was measured using ultrasonography between January and December 2017 and January and December 2021. We examined the association between baseline PTG volume and calcimimetic doses after 4 years. Results: Of the 121 patients {median age 64 years [interquartile range (IQR) 54–72]}, 71 had PTG nodules on ultrasonography and the median total PTG volume was 34 mm3 (IQR 0–178). In the short dialysis vintage group, baseline parathyroid hormone levels tended to correlate with baseline calcimimetic doses; however, this trend was not observed in the extended dialysis vintage group. Baseline PTG volume correlated with the cinacalcet-equivalent calcimimetic dose (correlation coefficient 0.46; P < .001) after 4 years. The calcimimetic dose in the group with an estimated PTG volume >500 mm3 was ≈80 mg/day higher than that in the non-PTG nodule group after 4 years. In multivariate linear regression analysis, PTG volume >500 mm3 was associated with a high calcimimetic dose at 4 years in all analysis models. Conclusions: Assessing PTG volume using ultrasonography may help predict high calcimimetic doses.